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NOInhibition of angiogenesis is currently perceived as a promising strategy in the treatment of cancer. The anti-
angiogenicity of thalidomide has inspired a second wave of research on this teratogenic drug. The present
study aimed to investigate the anti-proliferative and anti-angiogenic activities of two thalidomide dithiocarba-
mate analogs by studying their anti-proliferative effects on human umbilical vein endothelial cells (HUVECs)
and MDA-MB-231 human breast cancer cell lines. Their action on the expression levels of IL-6, IL-8, TNF-α,
VEGF165, and MMP-2 was also assessed. Furthermore, their effect on angiogenesis was evaluated through
wound healing, migration, tube formation, and nitric oxide (NO) assays. Results illustrated that the proliferation
of HUVECs and MDA-MB-231 cells was not signiﬁcantly affected by thalidomide at 6.25–100 μM. Thalidomide
failed to block angiogenesis at similar concentrations. By contrast, thalidomide dithiocarbamate analogs exhibit-
ed signiﬁcant anti-proliferative action on HUVECs and MDA-MB-231 cells without causing cytotoxicity and also
showed powerful anti-angiogenicity in wound healing, migration, tube formation, and NO assays. Thalidomide
analogs 1 and 2 demonstrated more potent activity to suppress expression levels of IL-6, IL-8, TNF-α, VEGF165,
and MMP-2 than thalidomide. Analog 1 consistently, showed the highest potency and efﬁcacy in all the assays.
Taken together, our results support further development and evaluation of novel thalidomide analogs as anti-
tumor and anti-angiogenic agents.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Thalidomide was ﬁrst synthesized in the 1950s by a German phar-
maceutical company and marketed as a sedative. However, pregnant
women began using thalidomide as a morning sickness drug because
it helped to relieve their nausea. It was soon discovered that thalido-
mide is highly teratogenic, causing severemalformations in the children
of womenwho took the drug during pregnancy [1,2]. Consequently, the
drug never gained approval in the United States and was taken off the
world market in 1961. In recent years, interest in thalidomide has
been renewed because it appears promising for the treatment of lepro-
sy. In 1998, the FDA approved thalidomide in the United States for
treating erythemanodosum leprosum (ENL). The clinical efﬁcacy of tha-
lidomide in inﬂammatory and autoimmune diseases has been partly at-
tributed to its ability to inhibit tumor necrosis factor-alpha (TNF-α)
production [3–5].81 86 251 8216.
. This is an open access article underOver three decades ago, Folkman [6] introduced the notion that
solid tumors cannot grow beyond 2–3 mm3 without the formation of
new blood vessels. Inhibition of angiogenesis has thereafter been per-
ceived as a promising strategy for treating cancer. D'Amato et al. [7]
demonstrated that thalidomide inhibits basic ﬁbroblast growth factor-
induced angiogenesis in the rabbit cornea and tumor growth in rabbits.
Subsequently, the anti-tumor activity of thalidomide has been evaluat-
ed in numerous clinical trials. Partial response, stable disease, or tumor
regression has been reported in patientswithmultiplemyeloma [8–10],
AIDS-related Kaposi's sarcoma [11], high-grade gliomas [12], hepatocel-
lular carcinoma [13,14], renal cell carcinoma [15,16] and advanced
melanoma [16]. In androgen-independent prostate cancer, thalidomide
has been found to cause a reduction in serum prostate-speciﬁc antigen
and an improvement in clinical symptoms [17].
Angiogenesis is a crucial regulator of tumor growth and metastasis
[18]. Tumor angiogenesis, the development of new blood vessels by the
tumor, is regulated by the production of angiogenic stimulators including
vascular endothelial growth factor (VEGF). Because VEGF is a key regula-
tory factor in the prognosis of various cancers, inhibition of VEGF produc-
tion is a promising therapeutic approach for treating cancer [19].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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stream, acts as pro-angiogenic factor [20]. Thalidomide inhibits TNF-α
by stimulating the degradation of messenger RNAs (mRNAs) that
involved in immune responses, the stimulation of inﬂammation, and
the suppression of certain cytokines [21–23].
Nitric oxide (NO), an important secondmessenger inmany signaling
pathways, is a potent vasodilator [24]. NO is produced by the action of
nitric oxide synthase (NOS) in the transformation of arginine to citrul-
line and activates soluble guanylate cyclase to produce cGMP [25]. NO
is involved in angiogenesis and endothelial cell (EC) migration [26]. As
thalidomide interferes with angiogenesis, a process in which NO also
plays a crucial role, we speculate a cross talk between thalidomide
and NO signaling pathway.
Dithiocarbamates have also been attracting considerable interest
because of their diverse activities. Dithiocarbamate derivatives have
been described as anti-fungals [27], anti-bacterials [28], and carbonic
anhydrase inhibitors [29,30]. In particular, their applications in the
treatment of cancer have been explored [31,32]. Our group recently
reported the synthesis of a novel thalidomide-containing dithiocarba-
mate moiety; several derivatives exhibited potent anti-cancer activi-
ty [33,34].
The present study aimed to investigate the anti-proliferative and
anti-angiogenic activities of two thalidomide dithiocarbamate ana-
logs by studying their ability to reduce the proliferation of human
umbilical vein endothelial cells (HUVECs) and cells from the MDA-
MB-231 human breast cancer cell line. Their effect on the expression
of mRNAs encoding interleukin-6 (IL-6), interleukin-8 (IL-8), and
TNF-α, VEGF165, and matrix metalloproteinase-2 (MMP-2) was also
determined. Moreover, we evaluated their effect on angiogenesis
through wound healing, migration, tube formation, and NO assays.2. Materials and methods
2.1. Thalidomide and its dithiocarbamate analogs
Thalidomide and its dithiocarbamate analogs 1 and 2 were synthe-
sized by Dr. Zahran and his group at Menoﬁa University, Egypt. World-
wide patents covering these analogs have been ﬁled. Their chemical
structures are shown in Fig. 1. The thalidomide analogs were synthe-
sized according to a previously described procedure [33]. Stock solu-
tions (30 mM) of thalidomide and its analogs were prepared in
dimethylsulfoxide (DMSO), stored at 4 °C, and then diluted as required.2.2. Cell lines and cell culture
HUVECs (CC2517, Lonza) were maintained in cell culture ﬂasks
coated with 0.1% gelatin (Wako Pure Chemical Industries, Ltd) and
cultured in endothelial cell basal medium (EBM™, Cat. No. CC-3121,
Lonza) supplemented with endothelial cell growth medium (EGM™Fig. 1. Chemical structures of thalidomide aSingleQuots™, Cat. No. CC-4133, Lonza). Conﬂuent cultures of HUVECs
were serially passaged and used between passages 3 and 6.
MDA-MB-231 cells were obtained from RIKEN BRC, Japan. The cells
were grown and subcultured in Dulbecco's Modiﬁed Eagle's Medium
(DMEM) (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10%
fetal bovine serum (FBS) (PAA Laboratories, Pasching, Austria) and
100 μg/mL kanamycin (Nacalai Tesque, Kyoto, Japan). The cells were
maintained at 37 °C in a 5% CO2-humidiﬁed atmosphere. The culture
medium was replaced every other day.
2.3. MDA-MB-231 proliferation assay
The inhibition of the growth of MDA-MB-231 cells by thalidomide
and its dithiocarbamate analogs 1 and 2 was evaluated using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma-Aldrich, St. Louis, MO, USA) cleavage assay. The cells were
seeded in 96-well plates at 5 × 103 cells/well in DMEM supplemented
with 10% FBS. After 24 h of culture, thalidomide and its analogs were in-
dividually added in triplicate in a range of 6.25–100 μM, and the cells
were further cultured for 72 h. The cells were then exposed to MTT
(5 mg/mL in PBS) at a ﬁnal concentration of 1 mg/mL in culture for
4 h. Formazan crystals formed during the incubation period were dis-
solved overnight at 37 °C by adding 10% SDS containing 0.02 N HCl.
The absorbance was thenmeasured at 570 nm. To evaluate the viability
of cells treatedwith thalidomide analogs for 72 h, the cellswerewashed
twice with DMEM supplemented with 10% FBS and then further incu-
bated for 48 h in DMEM supplemented with 10% FBS. The number of
the viable cells was evaluated using the MTT cleavage assay, as de-
scribed above.
2.4. Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was isolated using an RNA puriﬁcation kit (Qiagen
RNeasy®) according to the supplier's protocol. First-strand complemen-
tary DNA (cDNA) synthesis was performed using an oligo-dT primer
and Superscript II reverse transcriptase (Invitrogen). qRT-PCR was per-
formed for IL-6, IL-8, TNF-α, VEGF165, MMP-2, and GAPDH using the
SYBR green method with a real-time PCR detection system (Roche).
Cycling conditions for ampliﬁcation of all genes, except VEGF165 and
MMP-2, were as follows: 95 °C for 5min, followed by 45 cycles of dena-
turation at 94 °C for 10 s, annealing at 60 °C for 20 s, and extension at
72 °C for 40 s. The ampliﬁcation conditions for VEGF165 and MMP-2 in-
cluded annealing at 64 °C for 20 s and 66 °C for 10 s and extension at
72 °C for 20 s and 72 °C for 12 s, respectively. The transcritical cycle
(Ct) valueswere recorded and the speciﬁcity for ampliﬁcationwas eval-
uated usingmelting curve analysis software (LightCycler® 480). Primer
sequences for qRT-PCR are listed in Table 1. The relative gene expression
levels were calculated using the comparative Ct(ΔΔCt) method, where
the relative expression was calculated as 2−ΔΔCt, and Ct represents the
threshold cycle [35], using GAPDH as the reference gene.nd its dithiocarbamate analogs 1 and 2.
Table 1
Primer sequences for qRT-PCR.
Name Forward primer sequence (5′–3′) Reverse primer sequence (5′–3′)
IL-6 AAATTCGGTACATCCTCGAC CCTCTTTGCTGCTTTCACAC
IL-8 TACTCCAAACCTTTCCACCC AAAACTTCTCCACAACCCTC
TNF-α GCCTGCTGCACTTTGGAGTG TCGGGGTTCGAGAAGATGAT
VEGF165 CCCTGATGAGATCGAGTACATCTT AGCAAGGCCCACAGGGATTT
MMP-2 ATGACAGCTGCACCACTGAG ATTTGTTGCCCAGGAAAGTG
GAPDH CAACGACCACTTTGTC GGTCTACATGGCAACTGTGAGG
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HUVECs were seeded in 96-well plates at 10 × 103 cells/well in
endothelial cell basal medium-2 (EBM™-2, Cat. No. CC-3156,
Lonza) supplemented with endothelial cell growth medium (EGM™-2
SingleQuots™, Cat. No. CC-4176, Lonza) and allowed to attach overnight
at 37 °C and 5% CO2. The culture medium was then aspirated and
fresh culture medium containing vehicle (0.3% DMSO), thalidomide,
or thalidomide analogs (6.25–100 μM) was added to each well. After
48 h, the number of viable cells was evaluated using the MTT cleavage
assay.2.6. HUVEC growth curve
HUVECs, 1 × 105, were seeded overnight in 24-well culture plate,
and then themediumwas changed with fresh EBM-2 medium contain-
ing either DMSO (0.3%), thalidomide analogs 1 or 2 (100 μM). After 24
and 48 h of treatments, the cells were washed with EBM-2 medium
and trypsinized with trypsin-EDTA (Lonza). The cell suspensions were
further added with trypan blue dye (Sigma) and then counted with
TC10 automated cell counter (Bio-Rad, Hercules, CA, USA). The cell
growth curves were established based on the number of viable cells
exhibiting trypan blue exclusion.2.7. Wound healing assay
HUVECs were seeded into a 24-well plate at 1 × 105 cells/well in
EBM™-2 supplemented with EGM™-2. After 24 h of incubation, each
conﬂuent monolayer was scratched using a 200-μL plastic pipette
tip to create a wounded cell-free area and then washed twice with
EBM™-2. The cells were incubated at 37 °C with vehicle (0.3% DMSO),
thalidomide, or thalidomide analogs in a concentration range of
12.5–100 μM in EBM™-2 supplemented with EGM™-2. The cells were
photographed at 0 and 24 h using an inverted microscope, CKX41
(Olympus, Tokyo, Japan), equipped with a digital camera, U-CMDA3
(Olympus). The distance between the edges of the cell-free areas was
measured using the imaging program DP2-BSW (Olympus). Cell migra-
tion was calculated using the following equation: %R= [1− (wound
length at T24 / wound length at T0)] × 100, where (%R) is the percent
recovery, T0 is the wound length at 0 h, and T24 is the wound length at
24 after injury [36]. Experiments were independently repeated thrice.2.8. Preparation of MDA-MB-231 conditioned medium (CM)
MDA-MB-231 cells were seeded at a density of 1 × 106 cells per
60 mm dish in DMEM medium supplemented with 10% FBS. After
24 h of culture, the cells were washed with DMEM medium supple-
mented with 2% FBS and incubated for an additional 48 h in the same
medium with vehicle (0.3% DMSO), thalidomide, or thalidomide ana-
logs (25 and 100 μM). The conditioned media (CM) were collected,
centrifuged to remove insoluble materials and then stored at−20 °C
until used in HUVEC migration assay.2.9. Cell migration assay
The migration of HUVECs was assayed in 24-well plates with
8 μm pore cell culture inserts (BD, Franklin Lakes, NJ, USA). HUVECs
(1 × 105), suspended in 200 μL of serum-free medium, were seeded
onto the upper compartment of the insert chamber. The lower chamber
was ﬁlled with 500 μL of MDA-MB-231 CM pretreated with vehicle
(0.3% DMSO), thalidomide, or thalidomide analogs (25 and 100 μM).
After 48 h incubation at 37 °C under 5% CO2, the insert chambers were
removed, and adherent cells on the bottom of each well were counted
under microscope, CKX41 (Olympus, Tokyo, Japan). The number of mi-
grated cells was normalized by the number of adherent cells in vehicle
control.
2.10. Tube formation assay
First, 96-well plates were coated (50 μL/well) with matrigel base-
ment membrane matrix (BD Biosciences). Following this, the plates
were allowed to polymerize at 37 °C under 5% CO2 for 30 min. HUVECs
were then seeded at 2 × 104 cells/well in EBM™-2 supplemented with
EGM™-2 containing vehicle (0.3% DMSO), thalidomide, or thalidomide
analogs (12.5–100 μM) and incubated at 37 °C under 5% CO2. After 8 h of
incubation, the tube structures were photographed using an inverted
microscope, CKX41 (Olympus, Tokyo, Japan), equipped with a digital
camera, U-CMDA3 (Olympus). The digital images were analyzed using
DP2-BSW imaging software. The circular images of the wells were
divided into segments and the stimulation was then quantiﬁed by
counting the number of branching points formed within each segment.
Experiments were independently repeated thrice.
2.11. Nitric oxide assay
HUVECs were seeded at a density of 1 × 106 into 60 mm culture
dishes for 24 h and then the medium was changed with fresh medium
containing either vehicle control (0.3% DMSO), thalidomide, or thalido-
mide analogs at concentrations of 25 and 100 μM for 48 h. Production of
NO by HUVECs was measured using Griess method [37] and according
to the indication on the non-enzymatic colorimetric NO assay kit
(Oxford Biomedical Research, USA). This step was performed by mea-
suring the accumulation of nitrites, a stable end product of NOmetabo-
lism, in the supernatant of HUVECs. Because theNOpresent in biological
ﬂuids is recovered in nitrate form, the supernatant was overnight treat-
ed with desired amount of washed and dried cadmium beads with agi-
tation at room temperature in order to reduce nitrate to nitrite. Finally,
the samples were mixed with an equal volume of freshly prepared
Griess reagent for 20 min. Absorbance of each sample was measured
at 540 nm using a microplate reader SH-9000 Lab (CORONA ELECTRIC
Co. Ltd., Hitachinaka, Japan). Concentrations of NO in the samples
were determined using a calibration curve generated with standard
sodium nitrite (NaNO2) solutions (0.5–100 μM).
2.12. Statistical analysis
The results are expressed as themean± standard deviation from at
least three independent experiments. The data were analyzed using
Student's t test. Differences yielding p values b 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. Effect of thalidomide and its dithiocarbamate analogs onMDA-MB-231
proliferation
As shown in Fig. 2A, compared with vehicle control (0.3% DMSO),
thalidomide dithiocarbamate analogs reducedMDA-MB-231 cell prolif-
eration in a concentration-dependent manner. However, only at higher
Fig. 2.Effect of thalidomide and its dithiocarbamate analogs onMDA-MB-231 cell viability.
(A) The inhibition of cell growth in the presence of thalidomide and its analogs 1 and 2 for
72 h. (B) The viable cells at 72 h were kept cultured without thalidomide and its analogs
up to 96 h. Cell numbers in each well were assessed using the MTT assay. The absorbance
at 570 nm corresponding to the initial number of the cells was deﬁned as 1.
Fig. 3. Effect of thalidomide and its dithiocarbamate analogs on gene expression. (A) Effect
of thalidomide and its analogs on expression of IL-6, IL-8, and TNF-αmRNA inMDA-MB-231
cells. (B) Effect of thalidomide and its analogs on expression of VEGF165 andMMP-2mRNA in
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MDA-MB-231 cell proliferation was not signiﬁcantly decreased by any
concentration of thalidomide (6.25–100 μM). However, analogs 1 and
2 potently reduced MDA-MB-231 cell proliferation at 25 μM, by 18.6%
and 36.5%, respectively. To determine whether the reduction of MDA-
MB-231 cell viability by thalidomide analogswas the result of cytotoxicity
or a growth-inhibitory effect, we analyzed the ability of MDA-MB-231
cells treatedwith 100 μMof thalidomide or its analogs for 72 h to resume
their growth in the next 24 h in the absence of thalidomide or its analogs.
Results illustrated that compared with vehicle control (0.3% DMSO),
MDA-MB-231 cells can resume their growth in the next 48 h (Fig. 2B).
Therefore, we suggest that these thalidomide analogs inhibit the growth
of MDA-MB-231 through a cytostatic effect and not a cytotoxic effect.MDA-MB-231 cells. (C) Effect of thalidomide and its analogs on expression of VEGF165 and
MMP-2 mRNA in HUVEC cells. Data are presented as mean ± standard deviation. Signiﬁ-
cantly (*p b 0.1, **p b 0.05, ***p b 0.01) different from the vehicle control.3.2. Effect of thalidomide and its dithiocarbamate analogs on the expression
of mRNAs encoding IL-6, IL-8, TNF-α, VEGF165, and MMP-2
During tumor angiogenesis, VEGF is primarily produced by tumor
cells. It induces the formation of new vessels in the direction of the
tumor [38]. VEGF production by tumor cells is thought to be one of
the most speciﬁc and critical regulators of the angiogenic signaling cas-
cade [39]. VEGF production can be augmented by many factors, includ-
ing IL-6, IL-8, and TNF-α [40].
Therefore, the effect of thalidomide and its dithiocarbamate analogs
on the expression levels of IL-6, IL-8, TNF-α, VEGF165, andMMP-2mRNA
in MDA-MB-231 was investigated. As shown in Fig. 3A and B, thalido-
mide at 25 μM had no effect on the expression levels of IL-6, IL-8, TNF-
α, VEGF165, andMMP-2, while, it diminished the same expression levelsat 100 μMby57.3%, 56.3%, 40%, 34.3% and 26.3%, respectively, compared
with the vehicle control. Conversely, thalidomide analogs showedmore
potency than thalidomide toward the expression levels of IL-6, IL-8,
TNF-α, VEGF165, and MMP-2. Because, analog 1 at 100 μM showed
more potent inhibition of IL-6, IL-8, TNF-α, VEGF165, and MMP-2 (by
78%, 79.7%, 79%, 52.3% and 43.7%, respectively) than analog 2 (which
reduced the same expression levels by 64.7%, 48%, 56%, 41.3% and 38%,
respectively), relative to the vehicle control.
In HUVEC cells, thalidomide at 25 μMhad no signiﬁcant effect on the
expression levels of VEGF165 and MMP-2 compared with the vehicle
control, whereas, it diminished the same expression levels at 100 μM
by 31% and 22.7%, respectively. By contrast, analog 1 at 100 μM showed
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respectively) than analog 2 (which reduced the same expression
levels by 43.7% and 32.3%, respectively), relative to the vehicle con-
trol (Fig. 3C).
3.3. Effect of thalidomide and its dithiocarbamate analogs on HUVEC
proliferation
Endothelial cell proliferation is one of the complex multistep
processes involved in angiogenesis [41]. Therefore, the ability of thalid-
omide and its dithiocarbamate analogs 1 and 2 to inhibit the prolifera-
tion of endothelial cells was examined. As shown in Fig. 4, HUVEC
proliferation was not signiﬁcantly decreased by any concentration of
thalidomide (6.25–100 μM). By contrast, analog 1 signiﬁcantly reduced
HUVEC proliferation at 50 μMby 43.3%. Comparedwith the vehicle con-
trol (0.3% DMSO), analog 2 reduced HUVEC proliferation by 51.6%, but
only at the highest concentration. To determine whether the reduction
in HUVEC viability caused by thalidomide analogs was due to cytotoxic-
ity or a growth-inhibitory effect, we analyzed the growth curves
of HUVECs treated with vehicle control (0.3% DMSO), analogs 1 or 2
(100 μM) for 48h. As shown in Fig. 4B, HUVECnumber of vehicle control
increased from 1 × 105 cells at day 0 to 1.4 × 105 cells at day 1.While in
the presence of 100 μM of analogs 1 or 2 the numbers of HUVECs afterFig. 4. Effect of thalidomide and its dithiocarbamate analogs on HUVEC viability. (A) The
inhibition of cell growth in the presence of thalidomide and its analogs 1 and 2 for 48 h.
Cell numbers in each well were assessed using the MTT assay. The absorbance at
570 nm corresponding to the initial number of the cells was deﬁned as 100%. (B) The
growth curves of HUVEC treated with control (0.3% DMSO) or thalidomide analogs
(100 μM) for 24 and 48 h. Data are presented asmean± standard deviation. Signiﬁcantly
(**p b 0.05, ***p b 0.01) different from vehicle control at the same time point.24 h were 1.02 × 105 and 1.06 × 105, respectively. The growth
rate revealed that HUVEC numbers treated with analogs 1 or 2 started
to increase to be 1.78 × 105 and 2.17 × 105, respectively but cell
numbers were still signiﬁcantly lower than the vehicle control at 48 h.
Consequently, we can propose that thalidomide analogs exerted
growth-inhibitory effect on HUVECs but without causing signiﬁcant
cytotoxicity.
3.4. Effect of thalidomide and its dithiocarbamate analogs onHUVECmigra-
tion through wound healing assay
The wound-healing model is used to estimate the migration poten-
tial of endothelial cells in monolayer culture [42]. Therefore, the
wound healing migration assay was performed to determine the effect
of thalidomide and its dithiocarbamate analogs 1 and 2 on HUVEC mi-
gration. As shown in Fig. 5A, HUVEC migration was not signiﬁcantly re-
duced by any concentration of thalidomide, in a range of 12.5–100 μM,
within 24 h. On the other hand, analog 1 was found to be more potent
and efﬁcacious (inhibiting migration at 25 μM by 32.2%) than analog 2
(which signiﬁcantly reduced migration only at the highest concentra-
tion by 62.2%). Representative migration images are shown in Fig. 5B.
To prove that the change in wound distance after 24 h was due to the
effect of thalidomide and its analogs on the migration of endothelial
cells, and not due to their effect on endothelial cell proliferation, we
measured endothelial cell proliferation using identical concentrations
of thalidomide and its analogs during the same time of exposure. Prolif-
eration was measured using the trypan blue exclusion method. The
results (data not shown) demonstrated that there was no loss of endo-
thelial cell viability.
3.5. Effect of thalidomide and its dithiocarbamate analogs on migration
ability of HUVEC co-cultured with MDA-MB-231
To check the effect of thalidomide and its dithiocarbamate ana-
logs 1 and 2 on the migration ability of HUVEC co-cultured with
MDA-MB-231 CM, we ﬁrstly treated MDA-MB-231 cells with vehicle
(0.3% DMSO), thalidomide, or thalidomide analogs (25 and 100 μM) for
48 h, then CMwas harvested and its angiogenic activity was checked by
examining the level of HUVEC migration. Compared with the vehicle
control, HUVEC migration was not signiﬁcantly reduced by CM pre-
treatedwith thalidomide (25 or 100 μM)within 48 h (Fig. 6). Conversely,
MDA-MB-231 CM pre-treated with thalidomide analog 1 was found to
be more effective (inhibiting HUVEC migration at 25 μM by 35.58%)
than CM pre-treated with thalidomide analog 2 (which signiﬁcantly re-
duced HUVECmigration at 25 μM by 23.68%), relative to vehicle control.
3.6. Effect of thalidomide and its dithiocarbamate analogs on HUVEC
tube formation
To investigate the morphogenic potential of thalidomide and its di-
thiocarbamate analogs 1 and 2, a tube formation assay was performed.
This assay is one of the most popular in vitro angiogenesis tests [43].
As demonstrated in Fig. 7A, thalidomide in the concentration range of
12.5–100 μM failed to signiﬁcantly block tube formation. Tube forma-
tion appeared to be more sensitive to the effect of thalidomide analogs.
Compared with the vehicle control (0.3% DMSO), signiﬁcant inhibitions
of 86.4% and 64.3% were observed at 12.5 μM with analogs 1 and 2,
respectively. Representative tube images are shown in Fig. 7B.
3.7. Effect of thalidomide and its dithiocarbamate analogs on NO production
NO plays a crucial role in angiogenesis process and migration of
endothelial cells [26]. Therefore, the effect of thalidomide and its ana-
logs 1 and 2 on NO production level in HUVEC was studied. As shown
in Fig. 8, thalidomide failed to signiﬁcantly reduce NO production level
in HUVEC supernatants either at 25 or 100 μM. On the other hand,
Fig. 5. Effect of thalidomide and its dithiocarbamate analogs on HUVECmigratory ability. (A) The percent recovery as determined in the scratch-wound assay. Data are presented
asmean± standard deviation. Signiﬁcantly (**p b 0.05, ***p b 0.01) different from vehicle control. (B)Representative images ofwounds treatedwith the vehicle control (0.3%DMSO),
thalidomide, or thalidomide dithiocarbamate analogs at 100 μM.
Fig. 6. Effect of thalidomide and its dithiocarbamate analogs onmigration ability of HUVEC
co-cultured with MDA-MB-231, as determined in the migration assay. Translocated
cell numbers were normalized against those in the vehicle control. Data are presented as
mean ± standard deviation. Signiﬁcantly (**p b 0.05, ***p b 0.01) different from vehicle
control.
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respectively at 25 μM in comparison with the vehicle control (0.3%
DMSO). Furthermore, NO production was more sensitive to the effect
of thalidomide analogs at 100 μM, as signiﬁcant inhibitions of 24.51%
and 18.65% were observed with analogs 1 and 2, respectively.
4. Discussion
Cancer, a leading cause of death globally, causes almost 8 million
deaths each year and poses a major socioeconomic hazard to humanity
at large. Among all factors resulting in the ultimate failure of cancer
treatment, drug resistance is a signiﬁcant player [44]. The development
of new molecules to ﬁght cancer is urgently required because most
anticancer drugs are ineffective owing to drug resistance. Molecular
hybridization, which covalently combines two or more drug pharma-
cophores into a singlemolecule, is an effective tool to design highly active
novel entities [45]. These merged pharmacophores may act on multiple
therapeutic targets and offer the possibility of circumventing drug resis-
tance. In addition, the hybrids also minimize unwanted side effects and
enable synergic action [46]. Themolecular hybridization approach has al-
ready been applied to the development of novel antimalarial agents for
overcoming drug resistance [47]. Due to the anti-angiogenic properties
Fig. 7. Effect of thalidomide and its dithiocarbamate analogs on HUVEC capillary morpho-
genesis. (A) The number of branching points formed within each segment. Data are pre-
sented as mean ± standard deviation. Signiﬁcantly (*p b 0.1, **p b 0.05, ***p b 0.01)
different from the vehicle control. (B) Representative images from the tube formation
assay showing a higher potency of thalidomide dithiocarbamate analogs than that of
thalidomide. Vehicle control is 0.3% DMSO.
289B.Y.A. El-Aarag et al. / International Immunopharmacology 21 (2014) 283–292of thalidomide [7,48] as well as the numerous biological activities of di-
thiocarbamates and their application in cancer treatment [49,50], the
idea of combining or merging thalidomide and a moiety of dithiocarba-
mate caught the attention of our research group. This approach wasFig. 8. Effect of thalidomide and its dithiocarbamate analogs on NO production level in
HUVEC cells. Data are presented as mean ± standard deviation. Signiﬁcantly (**p b 0.05,
***p b 0.01) different from the vehicle control.pursued to design and synthesize new bioactive molecules with higher
activity than thalidomide itself. In addition, thalidomide dithiocarbamate
analogs had no negative co-later effects and this was obviously noticed
from our previous study which showed that they had no necrotic effect
on the liver of tumored mice compared with the liver of mice treated
with the parent thalidomide [33,34].
The present study was designed to investigate the anti-proliferative
and anti-angiogenic activities of two thalidomide dithiocarbamate
analogs in comparison with the activity of parent thalidomide against
HUVECs and the MDA-MB-231 breast cancer cell line.
Angiogenesis is the process of generating new capillary blood
vessels. It plays an important role in the proliferation, invasion, and
metastasis of malignant tumors. Blocking tumor-induced angiogene-
sis continues to be an attractive strategy for cancer therapy [51]. As
shown in our results, MDA-MB-231 proliferation was not signiﬁcant-
ly reduced by any concentration of thalidomide in a range of
6.25–100 μM. On the other hand, compared with vehicle control
(0.3% DMSO), analogs 1 and 2 potently reduced MDA-MB-231 prolifer-
ation at 25 μM by 18.6% and 36.5%, respectively (Fig. 2A). This ﬁnding
was consistentwith a previous report that thalidomide analogs contain-
ing sulfur atoms have greater inhibitory activity than thalidomide on
Ehrlich ascites carcinoma cell lines [33]. Thalidomide analogs inhibited
MDA-MB-23 cell proliferation through cytostatic effects rather than cy-
totoxic effects. This was demonstrated by the ability of MDA-MB-231
cells treated with 100 μM of thalidomide analogs for 72 h to resume
their growth in the next 24 h in the absence of thalidomide or its
analogs (Fig. 2B). Consequently, we conclude that the greater inhibitory
activity of these analogs than thalidomide may be attributed to the
presence of the dithiocarbamate group in their chemical structures.
Tumor angiogenesis has been recently observed to correlate with
hypoxia and the inﬂammatory process within the tumor [38]. When a
solid tumor grows beyond 2 mm in diameter, insufﬁciency of oxygen
and nutrients becomes obvious. Hypoxia in the inner part of the
tumorwill attract the inﬁltration of many inﬂammatory cells. Many fac-
tors are produced from the hypoxic region of the tumor and inﬂamma-
tory cells, including IL-6, IL-8, TNF-α, and VEGF. All these factors are
involved in tumor angiogenesis. Therefore, the effect of thalidomide
and its dithiocarbamate analogs on the expression of IL-6, IL-8, TNF-α,
VEGF165, and MMP-2 mRNA was investigated. As shown in Fig. 3A and
B, compared with vehicle control, thalidomide at 100 μM diminished
the expression levels of IL-6, IL-8, TNF-α, VEGF165, and MMP-2 mRNA
inMDA-MB-231 cells by 57.3%, 56.3%, 40%, 34.3%, and 26.3%, respective-
ly. Theseﬁndings are consistent with a previous report that thalidomide
suppresses the induction of VEGF in co-cultures of multiple myeloma
cell lines and bone marrow stromal cells [52]. In addition, thalidomide
inhibited the expression of VEGF and IL-6, which is thought to be the
mechanism underlying the attenuation of angiogenesis by thalidomide
[52]. Moreover, the inhibition of TNF-α production was initially consid-
ered to be a key mechanism of action of thalidomide [4].
On the other hand, analog 1 at 100 μM demonstrated more potent
inhibition ability to suppress the expression levels of IL-6, IL-8, TNF-α,
VEGF165, and MMP-2 in MDA-MB-231 cells (by 78%, 79.7%, 79%, 52.3%,
and 43.7%, respectively) than analog 2 (which reduced the same expres-
sion levels by 64.7%, 48%, 56%, 41.3%, and 38%, respectively), relative to
the vehicle control. Reportedly, thalidomide reduces the production of
TNF-α by enhancing TNF-αmRNA degradation [4]. In addition, Rosinol
et al. [53] stated that the decrease in circulating levels of VEGF correlates
with the therapeutic efﬁcacy of thalidomide in patients with multiple
myeloma andmyelodysplastic syndromes. Furthermore, IL-6 is a potent
growth factor for malignant plasma cells, and its inhibition may be
partly responsible for the action of thalidomide in myeloma [54]. IL-8
promotes leukin chemotaxis into tumors, leading to tumor neovascular-
ization and acceleration of tumor growth andmetastasis [55]. Therefore,
the activity of thalidomide analogs could be interpreted to be resulting
from the viability of these analogs, particularly analog 1, to effectively
reduce the expression levels of IL-6, IL-8, TNF-α, VEGF165, and MMP-2.
290 B.Y.A. El-Aarag et al. / International Immunopharmacology 21 (2014) 283–292Thus, the more potent inhibitory effects of the thalidomide analogs in
comparison with the effects of the parent thalidomide may be attribut-
ed to the presence of the sulfur atoms in these novel compound
structures. This changemay have led to an increase in inabilities to sup-
press the levels of IL-6, IL-8, TNF-α, VEGF165, and MMP-2 mRNA
expression.
To gain additional insight into the anti-angiogenic activity of thalid-
omide dithiocarbamate analogs, their ability to inhibit HUVEC prolifera-
tion, migration, and tube formation was assessed.
The proliferation of endothelial cells is considered to be a primary
event in angiogenesis and is therefore a potential target for anti-tumor
therapy [41]. Therefore, the anti-proliferative activity of thalidomide
and its analogs against HUVECs was investigated. The results demon-
strated that HUVEC proliferation was not signiﬁcantly decreased by
any concentration of thalidomide in a range of 6.25–100 μM. By con-
trast, compared with vehicle control (0.3% DMSO), thalidomide analogs
signiﬁcantly reduced HUVEC proliferation, as shown in Fig. 4A. Parallel
to our ﬁnding, Ng et al. [56] observed that thalidomide, at concentra-
tions of 12.5–200 μM, failed to inhibit HUVEC growth, while other N-
substituted analogs signiﬁcantly inhibited cell proliferation. Thalido-
mide analogs inhibited HUVEC proliferation through a cytostatic effect
rather than a cytotoxic effect. This was deduced from the growth curves
of HUVEC treated with 100 μM of thalidomide analogs 1 and 2 for 48 h
(Fig. 4B). This suggests that the replacement of the imido hydrogen in
the glutarimide ring (N-substitution) with dithiocarbamate moieties
generated analogs with more potent anti-proliferative activity than
thalidomide.
Endothelial cells serve as a barrier between the intravascular com-
partment and the surrounding tissues. Thus, they are directly exposed
to various stresses, including hypoxia and insufﬁcient nutrient supply.
If the stress is sufﬁciently severe to cause endothelial injury, wound re-
pair processes are immediately initiated to restore this barrier function.
Wound repair is a complex process that includes cell adhesion, migra-
tion, and proliferation [57].
Our data, throughwound healing assay, showed that HUVECmigra-
tion was not signiﬁcantly reduced by thalidomide at concentrations of
12.5–100 μM; however, thalidomide analogs, particularly analog 1,
exhibited forceful activity to inhibit HUVEC migration (Fig. 5A). With
regard to thalidomide, our ﬁnding was in agreement with the previous
report [58], which mentioned that thalidomide at concentrations of
25–75 μM had no effect on the rate of endothelial cell migration, while
thalidomide at 150 μM caused only a 20% reduction in the rate of
wound healing.
In addition, Fig. 6 revealed that, compared with the vehicle con-
trol, HUVEC migration was not signiﬁcantly reduced by MDA-MB-
231 CM pre-treated with thalidomide, while CM pre-treated with
thalidomide analogs 1 and 2was found to bemore effective to inhibit
HUVEC migration. VEGF is probably the most important inducer of
angiogenesis, owing to its potency and selectivity for endothelial
cells and its ability to regulate the proliferation and migration of en-
dothelial cells [57,59]. MMP-2, predominately expressed in the en-
dothelial cells, was directly involved in endothelial cell migration
and vascular remodeling during angiogenesis [60,61]. Moreover,
the present study revealed that thalidomide analogs, particularly ana-
log 1, demonstrated potent activity to reduce the expression levels of
MMP-2 and VEGF165 (Fig. 3C). In addition, they strongly suppressed
HUVEC proliferation (Fig. 4). Thus, the potency of both analogs, partic-
ularly analog 1, to reduce HUVECmigration could be related to their po-
tent inhibitory action onMMP-2 and VEGF expression levels in addition
to HUVEC proliferation.
The abilities of endothelial cells to differentiate in response to specif-
ic stimuli and to migrate out of existing blood vessels to organize new
capillaries are important for angiogenesis [38]. To examine themorpho-
genic potential of thalidomide and its analogs, we used an in vitro assay
that allows the visualization of multicellular tube-like structures, which
resemble microvascular networks, on matrigel.The results proved that thalidomide in a concentration range of
12.5–100 μM had no signiﬁcant effect on the formation of capillary
tubes. On the other hand, compared with vehicle control (0.3%
DMSO), signiﬁcant inhibitions of 86.4% and 64.3% were observed at
12.5 μM concentrations of analogs 1 and 2, respectively (Fig. 7A). With
regard to thalidomide, this ﬁnding was consistent with a previous re-
port that thalidomide at concentration of 12.5–200 μM failed to block
angiogenesis in vitro, while some thalidomide analogs signiﬁcantly
inhibited microvessel outgrowth [56].
With regard to thalidomide analogs, it has been suggested that TNF-
α indirectly mediates the angiogenesis process and that its mechanism
maydependon the synthesis of secondarymediators, including IL-8 and
VEGF [62–65]. Furthermore, VEGF plays a pivotal role in normal and
pathological angiogenesis because its activation triggers multiple sig-
naling networks that result in endothelial cell survival, mitogenesis, mi-
gration, and differentiation [66]. Moreover, IL-8 mediates the inhibition
of endothelial cell apoptosis, endothelial cell proliferation, and capillary
tube formation [67]. Therefore, the maximum inhibition of tube forma-
tion was observed with thalidomide analogs, particularly analog 1. This
is expected from the present study because thalidomide analogs, partic-
ularly analog 1, demonstratedmore potent ability to reduce the expres-
sion levels of IL-6, IL-8, TNF-α, VEGF165, andMMP-2. They also exhibited
strong suppression of HUVEC proliferation and migration.
NO is an important physiologicalmessenger and effectermolecule in
many biological systems, including immunological, neuronal and car-
diovascular tissues [68,69]. It plays an important role in various phe-
nomenon involved in angiogenic process by modulating the activity of
angiogenic factor released by tumor cells such as VEGF [70]. As shown
in Fig. 8, thalidomide failed to signiﬁcantly reduce NO production level
in HUVEC supernatants either at 25 or 100 μM (Fig. 8). This ﬁnding is
consistent with previously reported results which concluded that tha-
lidomide has been found to exhibit weak NOS inhibitory activity [71].
On the contrary, level of NO productionwas reduced after the treatment
of HUVECs with analogs 1 and 2. This potency of both analogs, particu-
larly analog 1, to reduce NO production level could be related to their
potent inhibitory effect on the VEGF expression. Recent studies showed
that VEGF increases NO production in rabbit or human endothelial cells
and NO is thought to be an important mediator in VEGF-induced endo-
thelial cell proliferation [72,73].
In summary, our results suggest that the anti-cancer action of syn-
thetic thalidomide dithiocarbamate analogs results from both direct ac-
tion in cancer cells (inhibition of growth as well as IL-6, IL-8, TNF-α,
VEGF165, andMMP-2 expression levels) and indirect action through en-
dothelial cells (inhibition of proliferation,migration, and tube formation
as well as NO production). These ﬁndings further suggest that thalido-
mide dithiocarbamate analogs may be excellent leads for the develop-
ment of anti-angiogenic and anti-cancer drugs.Acknowledgments
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